Free press releases distribution network?

Agency / Source: IPSEN Group

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib - Clinical trial will also explore single-agent activity of cabozantinib in the first-line setting [Nasdaq: EXEL] - Exelixis.com / ClinicalTrials.gov / IPSEN.com
Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib

 

PRTODAY - Newswire & PRZOOM/ - Alameda, CA, United States, 12/05/2018 - Clinical trial will also explore single-agent activity of cabozantinib in the first-line setting [Nasdaq: EXEL] - Exelixis.com / ClinicalTrials.gov / IPSEN.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (cosmic-312) of Cabozantinib in Combination with Atezolizumab Versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma

Exelixis, Inc. and Ipsen today announced the initiation of COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) versus sorafenib in previously untreated advanced hepatocellular carcinoma (HCC). The co-primary endpoints of the trial are progression-free survival and overall survival. An exploratory arm will also evaluate cabozantinib monotherapy in this first-line setting.

“Liver cancer is the fastest-rising cause of cancer-related death in the U.S., underscoring the need for new treatment options for this patient community,” said Gisela Schwab, M.D., President, Product Development and Medical Affairs and Chief Medical Officer, Exelixis. “Based on past evidence of potential synergistic effects with cabozantinib and immune checkpoint inhibitors, the combination offers promise for patients with advanced liver cancer who have not received prior treatment.”

COSMIC-312 is a multicenter, randomized, controlled phase 3 pivotal trial that aims to enroll approximately 640 patients at up to 200 sites globally. Patients will be randomized 6:3:1 to one of three arms: cabozantinib (40 mg) and atezolizumab, sorafenib, or cabozantinib (60 mg).

Exelixis is sponsoring COSMIC-312, and Ipsen will co-fund the trial. Ipsen will have access to the results to support potential future regulatory submissions outside of the U.S. and Japan. Genentech, a member of the Roche Group, is providing atezolizumab for use in this trial.

“With more than 800,000 new diagnoses of liver cancer worldwide each year and a poor prognosis for patients with advanced disease, there is an urgent need to identify new treatment options,” said R. Kate Kelley, M.D., Associate Professor of Clinical Medicine, Division of Hematology/Oncology, University of California, San Francisco, and lead investigator on COSMIC-312. “We look forward to learning whether the combination of cabozantinib and atezolizumab may improve outcomes for previously untreated patients.”

More information about this trial is available at ClinicalTrials.gov/.

About Exelixis

Founded in 1994, Exelixis, Inc. (exelixis.com) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in need. We discovered our three commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed
products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of Standard & Poor’s
(S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.

About Ipsen

Ipsen (ipsen.com) is a global biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries.

Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US).

The Group has about 5,400 employees worldwide. Ipsen is listed in Paris and in the United States through a Sponsored Level I American Depositary Receipt program.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: IPSEN Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+] [Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
Ipsen | Exelixis, Inc.
Contact: Ian Weatherhead - IPSEN.com 
+44(0)17 5362 7733 ian.weatherhead[.]ipsen.com
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Pharma/BioTech/Nutrition via RSS
AddThis press release: Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus SorafenibAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From IPSEN Group / Company Profile



Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen and 3BP Announce First Patient Dosed in Phase I/II study for First-in-Class Radionuclide (IPN01087)
EC Approves Ipsen’s Cabometyx® (cabozantinib) for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan
Market Entrants Offering Digitized Mass Spectrometry Solutions Gain a Competitive Edge over Traditional Vendors Finds Frost & Sullivan
FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
Medtech & Pharma Platform Annual Event Celebrates its 5th Anniversary in Basel
Ipsen to Present New Data from its Oncology Portfolio At The 2018 European Society for Medical Oncology (ESMO) Congress
Arla Foods Ingredients Acclaimed by Frost & Sullivan for its Osteopontin-enriched ingredient, Lacprodan® OPN-10
SCHOTT Teams Up with Smart Skin Technologies
STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture System

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit  BizJobs.com

Visit  RightITnow, Inc.

Visit  JobsWare.com





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)